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Objective: Effects of pump treatment vs. four times daily injections were
explored in children with diabetes with regard to quality of life and
impact of disease as well as adverse effects and parameters of metabolic
control.
Methods: An open, parallel, randomized controlled prospective com-
parative study lasting 14 months was completed by 38 type 1 children
with diabetes (age 4–16 yr) following a 3.5-months run-in phase.
Standardized quality-of-life Pediatric Quality of life Inventory (PedsQL)
and impact of disease scores were obtained every 3.5 months as well as
regular medical parameters. Parallel treatment group data and longitu-
dinal within-patient data were analysed for each treatment modality.
Results: Within-patient comparisons of the two treatment modalities
showed significant improvement in PedsQL and impact scores after pump
treatment. Treatment group comparisons did not show significant
improvement. Pump treatment resulted in decreased symptomatic
hypoglycaemia and lowered haemoglobin A1c by 0.22% after run in.
Conclusions: Within-patient comparison suggests that metabolic control,
frequency of severe hypoglycaemia (a threefold decrease), quality of life
and impact of disease scores are improved by pump treatment in
comparison to regular treatment with four daily insulin injections.
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More than 1000 children have been enrolled over time
in either retrospective or non-randomized prospective
follow-up studies of continuous subcutaneous insulin
infusion (CSII) (1), some of which indicate a lasting
decrease of haemoglobin A1c (HbA1c) (2, 3). These
studies show that CSII is safe for use in children,
resulting in less hypoglycaemia and better HbA1c, with
some 30% lower daily insulin doses than when multiple
daily insulin injections (MDII) are applied. CSII was
considered beneficial by children and parents alike as
they experienced more treatment flexibility and com-
fort (4, 5) than with daily injections.
However, almost all these studies focused on
metabolic control rather than on parameters for quality
of life or impact of disease. Furthermore, only five ran-
domized comparisons have been published in children
comparing MDII, mostly four times daily, with insulin
pump therapy (CSII) (5–9), three of which were in
preschoolers (7–9). In contrast to non-randomized
surveys, only one of those reported a significantly lower
HbA1c with CSII (6). None of the randomized
paediatric studies was preceded by a proper run-in
phase (10).
The aim of the present study was to investigate the
changes in quality of life and of impact of disease by
either CSII or MDII prospectively in a randomized
study preceded by a 3.5-month run-in phase of MDII,
following medical effects simultaneously.
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Methods
Patients
Study participation was sought in our own clinic and
nationwide by announcement in the Dutch Diabetes
Association’s monthly news bulletin. Thirty-nine pa-
tients were enrolled in 11 months time, 20 from our
own clinic and 19 referred for the duration of the
investigation. For 35 children (90%), both parents were
of Caucasian origin. None of the children had used an
insulin pump before for any length of time. Our clinic
had insulin pump experience since 1983, and at the
time of this study, 35% of the 120 children were on
insulin pumps. Ten of the 39 patients included sought
participation in the study because of frequent severe
hypoglycaemias (.4/year during the previous year),
severe hypoglycaemia defined as any hypoglycaemic
event requiring assistance from another person or
resulting in seizure or coma. Another six children
participated because of severely fluctuating glucose
levels with more than 3 weekly symptoms of milder
hypoglycaemia and/or capillary blood glucose levels
,3.8 mmol, for which ingestion of extra carbohydrates
was deemed necessary. The remaining 23 children were
included solely because of consistent HbA1c levels
above 8%.
Inclusion criteria were type 1 diabetes, diagnosed
by the presence of islet antigen-2, glutamic acid
decarboxylase-65 or islet cell cytoplasmic autoanti-
bodies, daily insulin administration for 1 yr or longer,
randomC-peptide,200 pmol,HbA1c . 8.0%,ahistory
of repeated symptomatic hypoglycaemias, age 4–16 yr,
and attendance of a regular school. Exclusion criteria
were clinically manifest chronic complications, preg-
nancy, co-morbidity, mental retardation, psychiatric
treatment or symptoms in a child or a parent, insufficient
Dutch language capabilities and absence of a telephone at
home.
The study protocol was approved by the Erasmus
University Medical Centre/Sophia Children’s Hospi-
tal’s Medical Ethical Technical committee. Written
consent was obtained from both parents and the
children if older than 12 yr prior to the study.
Study design
An open-label, randomized, prospective parallel design
was chosen to compare MDII with CSII (Fig. 1). All
management was on an out-patient basis. All measure-
ments, medical and psychological, were performed at
3.5 month  1 wk intervals. The Pediatric Quality of
life Inventory (PedsQL 4.0, Dutch version) (11) was
taken from all parents and from 37 of the 39
participating children older than 5 yr. Disease impact
scores were obtained from parents only, using the
Diabetes Quality of Life Questionnaire and omitting
the last 4 of the total of 23 impact questions, those that
are designed for children (12, 13). The interviews and
resulting scores were obtained by a single psychologist
every 3.5 months.
The study design included a 3.5-month run-in phase
on MDII for all children, consisting of injecting three
short-acting insulin doses s.c. before breakfast, lunch
and supper. During MDII, 26 children used insulin
aspart and 12 used regular insulin before meals. At
bedtime, longer acting s.c. insulins were given, 23 using
intermediate-acting insulin neutral protamine Hage-
dorn (NPH) and 15 insulin glargine. One child dropped
out after the run-in phase. For CSII, only insulin aspart
was used. The diabetes team was available 24 h/d for
consultation by telephone. Results of home blood glu-
cose monitoring three to four times daily were noted
in booklets throughout the study. New and carefully
calibrated Precision Xtra (Abbott, Alameda, CA,
USA) equipment was used for capillary blood glucose
measurement. Individualized insulin doses and dietary
adaptations were provided in writing for each child and
each child’s parents at each 5- to 6-wk clinic visit
throughout the study, the target blood glucose level
being 4–10 mmol. All patients were instructed to count
carbohydrates. Dietary advice was given every
3.5 months, based on written nutritional intake and
(n=38)
CSII group A
(n=19)
MDII group B
(n=19)
CSII Preference*
CSII Preference*
1.Start
Run in (MDII)
2.Start randomization 3.Start CSII phase 4.Start preference phase
0 (start) 3.5 months 7 months 10.5 months 14 months
5.End
Fig. 1. Flowchart of the randomized parallel trial design over time. Subjects in the two arms were followed during 3.5-monthly intervals.
Group A switched from multiple daily insulin injections (MDII) to continuous subcutaneous insulin infusion (CSII) at 3.5 months after the
start of the study. Group B followed after 7 months. *CSII phase because all patients chose to continue CSII.
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exercise reports 3 d before the visit. Injection sites were
checked at all visits and rotation advised accordingly
with intensive out-patient guidance, including the 24-h
telephone service. For CSII H-tron Disetronic insulin
pumps (Roche, Basel, Switzerland) were used, chang-
ing the infusion catheter every 2 d. CSII insulin dosage
was initiated as 75% of the total daily MDII dose,
mostly 50% as basal insulin day and night and 50%
premeal, including snacks.
After the 3.5 months of run-in phase, each child was
randomly assigned to either (ongoing) MDII or CSII
using the closed envelop’ method, supplied by the Public
Health Department. Comparison between MDII and
CSII was performed during 3.5 months, thereafter all
children continued with CSII for another 7 months by
unanimous preference. As shown in Fig. 1, after run
in, the choice of a parallel design for MDII vs. CSII
comparison resulted for group A children in 10.5-month
CSII treatment and for group B children in 3.5-month
MDII, followed by 7-month CSII treatment.
Capillary blood samples were sent to the national
standardization laboratory for determination of
HbA1c by high-performance liquid chromatography
[Dutch: SKZL, Winterswijk, the Netherlands, head
Dr C Weijkamp (IFCC)]. The HbA1c level in patients
without diabetes is 4.5–6.0% (14).
Statistical analysis
All data from the 38 children completing the studies
were analysed at baseline and at 3.5-monthly follow-
ups. Baseline characteristics were compared by
Levine’s independent t-tests. Parallel data were avail-
able from 19/38 children (Fig. 1) for the two random-
ized treatment arms, CSII (group A) andMDII (group
B). The data from these were compared by baseline-
adjusted repeated measures ANOVA with random
intercepts. Within-patient CSII data available from
all 38 children – over 10.5 months for group A and
7 months of CSII for group B – between initiation of
CSII and completion of the (unanimous) CSII prefer-
ence phase were compared using paired t-tests. This
time-spanwas chosen as the longest available. The level
of significance was set at p , 0.05 for all comparisons.
Results
Of the 39 children enrolled, 38 completed the study.
One 11-yr-old girl consistently refrained from the pump
phase of CSII after 3 wk because of its visibility on the
beach. Of the 38 children completing the study, 9 were
aged 4–7 yr, 22 were 8-12 yr and 7 were 13–16 yr.
Table 1 shows the baseline characteristics of the
children randomly assigned to group A (CSII) and
group B (MDII).
Table 2 contains the numerical data of ensuing
results of each study phase indicated by 1–5.
The upper part (groupA 1–5 and group B 1–5) shows
the results of treatment group analyses, with above the
results for group A, i.e., the children assigned by
parallel randomization to 3.5-months CSII, and below
those for group B, assigned to (ongoing) 3.5-months
MDII prior to CSII.
The lower part of Table 2 contains the data obtained
for the within-patient analysis of children having used
CSII during any of the study phases 1–5: 10.5 months
for group A and 7 months for group B children as
a result of the parallel design of the study (Fig. 1).
Adverse events
DuringMDII (Fig. 1), covering almost 17 patient years
in total, a high number of severe hypoglycaemias still
occurred, averaging 1.1 per patient year (group A was
onMDII for 3.5 months and group Bwas onMDII for
7 months, altogether almost 17 patient years). During
CSII, covering almost 28 patient years in total, severe
hypoglycaemia decreased to an average of 0.29 per
patient year, indicating amore than threefold reduction
of severe hypoglycaemia events. In the 3.5 months of
randomization, four severe hypos occurred in the
MDII group and two in the pump group. Admission
for ketoacidosis occurred four times for patients on
MDII (all in adolescents aged .12 yr) and two times
for one patient on CSII (an adolescent aged 14 yr).
Quality of life and impact of disease
The PedsQL scores (38 parents and 36 children aged
.5 yr) increased significantly during the run-in phase
(p ¼ 0.006 for parents and p ¼ 0.001 for children).
PedsQL scores remained stable while on MDII in the
randomization phase and increased non-significantly
Table 1. Baseline characteristics by randomization group
Group A
(CSII)
Group B
(MDII)
Age (yr) 10.0  3.0 10  3.7
n (number of female) 19 (12) 19 (9)
Duration (yr) 5.6  3.3 4.7  2.9
BMI SDS† 0.51  0.84 0.29  0.95
HbA1c % start run in 8.26  0.80 8.40  1.06
HbA1c % after run in 7.66  0.56 7.98  0.57
Daily insulin dose (U/kg/d)* 0.98  0.21 1.10  0.44
PedsQL, parents 78.3  10.2 74.5  13.4
PedsQL, children 79.4  11.3 79.2  9.5
Impact score, parents 46.2  8.7 42.7  8.8
CSII, continuous subcutaneous insulin infusion; MDII,
multiple daily insulin injections; PedsQL, Pediatric Quality
of life Inventory.
Data are presented as mean  SD. No significant differ-
ences were found for types of insulin used during the run-
in phase.
*p ¼ 0.029.
†Body mass index standard deviation score (BMI SDS)
according to Dutch reference, 1997 (15).
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by 2.5 points on average while on CSII (Table 2, upper
part, columns 3 and 4, rows 4 and 5). After completion
of the randomization, all 38 children were on CSII by
preferencewithbothPedsQLscores,maintaininga level
at an average of 10 points (85–90) higher than that at
baseline (75–80).
By contrast, within-patient analysis during CSII
involving 38 children during 7–10.5 months (Table 2,
lower part, columns 3 and 4) showed an increase of the
child-reported PedsQL scores from 84.1  11.3 to
87.3  11.6 (p ¼ 0.023) and an increase in parent-
reported PedsQL scores from 81.1  10.6 to
85.4  12.2 (p ¼ 0.025).
The impact of disease score (Table 2, lower part,
column2) in the run-inphasedecreasednon-significantly
from 44.5  8.8 to 42.4  7.8 (p ¼ 0.058) and also
non-significantly during the randomization phase. As
with the PedsQL score, the within-patient analysis
(Table 2, lower part, column 2) showed a significant
decrease in impact of disease from 41.7  8.7 to
38.2  8.3 (p ¼ 0.0063).
Glycaemic control
HbA1c significantly decreased in the run-in phase for
all 38participating children (Table 2, lower part, column
5, rows 16 and 17) from 8.34 to 7.82. (20.52%, p ¼
0.001). Fifteen children used glargine insulin at bedtime
and the other 23 children NPH insulin, but no signif-
icant differences were found in their HbA1c (%). No
differences were seen in HbA1c between the 12 regular
insulin users and the 26 insulin aspart users before meals.
A non-significantly but marked difference was seen
between theHbA1c at the start of the study between the
referred children (n ¼ 19) and the children from our
centre (n ¼ 19) (HbA1c 8.53 vs. 8.14%, p ¼ 0.2).
However at the start of the randomization phase, no
significant differences were seen between the referred
patients and the patients from our centre (HbA1c 7.89
vs. 7.7%, p ¼ 0.64).
The within-patient analysis (Table 2, lower part,
column 5, rows 18–19) showed a decrease in HbA1c at
the end of the 7- to 10.5-month CSII period by 0.22%
(p ¼ 0.02) while using an average of 0.27 U/kg/d less
insulin (Table 2, lower part, column 6, rows 18–19), p ,
0.001. Inkeepingwith this improvement, the subset of 13
children with HbA1c levels .8% at the start of CSII
(mean 9.1  1.0) showed a decrease inHbA1c to amean
of 8.56%  1.0 after 7–10.5 months of CSII (p ¼ 0.01).
Discussion
This is the only randomized prospective childhood
diabetes treatment study comparing MDII with CSII
preceded by an adequate run-in phase. It is telling that
only 1 of the 39 children aged 4–16 yr enrolled dropped
out from this demanding study lasting 14 months.
However, no significant (p , 0.05) improvement was
found in PedsQL nor in impact of disease scores during
the actual randomization phase when children in the
MDII condition were directly compared with those in
the CSII condition.
During run-in phase, PedsQL and impact of disease
scores improved significantly and so did HbA1c (from
Table 2. Outcome measures for group A (CSII) and group B (MDII)
Variable
Impact score,
parents
PedsQL PedsQL
HbA1c
Insulin
(U/kg/d)Children Parents
Cross-sectional analysis
Group A (CSII) (n ¼ 19)
1. Start 46.2  8.7# 79.4  11.4 78.3  10.2# 8.26  0.80# 0.98  0.21
2. After run in 42.8  7.8* 86.0  9.5 82.5  8.9* 7.66  0.56* 1.03  0.22#
3. After random (CSII) 40.2  8.5 88.8  9.0 86.2  6.1 7.49  0.50 0.71  0.13*
4. After CSII 40.5  9.8 87.8  9.9 83.7  10.7 7.53  0.67 0.74  0.12
5. After CSII 38.8  8.0 89.6  9.3 85.3  11.8 7.53  0.55 0.76  0.15
Group B (MDII) (n ¼ 19)
1. Start 42.7  8.8 79.2  9.5 74.5  13.4# 8.41  1.07# 1.10  0.44
2. After run in 41.9  8.4 81.9  11.6 78.6  12.5* 7.98  0.57* 1.07  0.32
3. After random (MDII) 40.6  9.5# 82.3  12.8# 79.7  12.2# 7.97  0.78 1.07  0.32#
4. After CSII 36.7  7.8* 86.1  10.5* 84.9  10.8* 7.76  0.90 0.77  0.17*
5. After CSII 37.6  8.7 85.0  13.3 85.5  12.9 7.65  0.88 0.78  0.20
Within-patient analysis
All children (n ¼ 38)
1. Start 44.5  8.8 79.3  10.3# 76.4  11.9# 8.34  0.93# 1.04  0.35
2. After run in 42.4  7.8 84.0  10.7* 80.6  10.9* 7.82  0.58* 1.05  0.27
2/3. Start CSII† 41.7  8.7# 84.1  11.3# 81.1  10.6# 7.81  0.69# 1.04  0.29#
5. End of study 38.2  8.3* 87.3  11.6* 85.4  12.2* 7.59  0.73* 0.77  0.18*
CSII, continuous subcutaneous insulin infusion; MDII, multiple daily insulin injections; PedsQL, Pediatric Quality of life
Inventory.
*p , 0.05, compared with the phase of the study mentioned one line above and marked with a #.
†Start of CSII for group A (2) and for group B (3); hence, group A was on CSII for 10.5 months and group B for 7 months.
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8.34 to 7.82%). It seems that these effects were stolen’
from the subsequent randomization phase comparing
MDIIwithCSII, whichmight explain themore positive
reports on childhood direct MDII vs. CSII compar-
isonswithout run in reported in other studies (6, 16–19).
A significant study effect could be caused by either
suboptimal treatment prior to the study or suboptimal
CSII treatment during the study proper. The 19
children who were referred to our clinic did show
a more pronounced decrease in HbA1c compared with
the 19 children enrolled fromour clinic (0.64 vs. 0.44%).
The study design allowed for a within-patient
analysis looking into the effects of CSII for 7.5–
11 months in all 38 participants. In this comparison,
PedsQL scores obtained from children and parents
improved and impact of disease scores obtained from
parents decreased significantly. One explanation for
this difference is statistical. Variance in scores by two-
way ANOVA (treatment group) will be larger than those
by paired t-tests (within patient). HbA1c improved by
0.22%. No significant correlations were found between
decrease of HbA1c and improvement of quality-of-life
parameters. The present HbA1c findings agree with
much larger studies in adults using a run-in phase (20).
In addition, the current study showed a threefold
decrease of severe hypoglycaemia when children were
in CSII treatment. The number of hypoglycaemic
events per child was however insufficient to test if this
is related to improved quality of life and/or lessened
impact of disease.
Limitations of our study are the limited power of the
study, with 19 patients in each study group and the
short duration of the randomization phase, only
3.5 months. Several studies showed that a longer
observation period is needed to obtain significant
differences between MDII and CSII (2, 3) Also the
findings raise the question whether the PedsQL and
impact of disease questionnaires used have enough
sensitivity to show improvement by CSII over MDII in
children of ages varying from 4 to 16 yr. It cannot be
excluded that the five repetitive assessments with 3.5-
month interval during this study suffered from carry-
over effects, although the trends of Table 2 do not
support this premise.
In conclusion, a threefold decrease in sever hypo-
glycaemia was observed in the CSII phase of this study,
and quality of life and impact of disease scores were
shown to improve by CSII when within-patient
analyses were performed but not when treatment
groups were compared. Better psychometric tools,
higher numbers of participants and longer observation
periods preceded by an adequate run-in phase will be
needed to definitely show that quality of life is
improved and impact of disease is diminished by CSII
in childhood diabetes. Such studies are needed to
underscore the fact that patients largely prefer CSII
over MDII (3, 5, 6, 16, 19).
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